EUVIMEDEUVIMED entdecken
Crossref

Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes

Marta Garcia-Guix iD, Alba Ardevol iD, Victor Sapena, Edilmar Alvarado-Tápias iD, Anna Huertas, Anna Brujats, Javier Fajardo, Berta Cuyas, María Poca, Carlos Guarner, Xavier Torras, Àngels Escorsell iD und 1 weitere

Liver International · 2024

DOI: 10.1111/liv.15937 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Marta Garcia-Guix und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Hypertension, Portal, Liver Cirrhosis, Ascites, Gastrointestinal Hemorrhage. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Decompensated‐cirrhosis encompasses several stages with different prognosis, such as bleeding, ascites and bleeding‐plus‐ascites. Development of further‐decompensation worsens survival, while non‐selective β‐blockers (NSBBs) can modify the risk. However, how this applies to each stage is uncertain. We aimed to investigate, in each stage of decompensated‐cirrhosis, the influence of further‐decompensation on mortality and whether changes in portal‐pressure (HVPG) under NSBBs influence these outcomes.

Methods

Patients with variceal bleeding were consecutively included differentiating those with bleeding‐alone from those who also had ascites. Patients with ascites and high‐risk varices referred for primary‐prophylaxis were also investigated. A baseline haemodynamic study was performed and was repeated after 1‐3‐months under NSBBs. Outcomes were investigated by competing‐risk.

Results

Totally 103 patients had bleeding‐alone, 186 bleeding‐plus‐ascites and 187 ascites‐alone. Mean follow‐up was 32‐months (IQR, 12–60). Patients with bleeding‐plus‐ascites had higher HVPG and were more hyperdynamic than patients with ascites‐alone and these than those with bleeding‐alone. At each stage, the mortality risk was more than twice in patients developing further‐decompensation vs. those without ( p < .001). In each stage, HVPG‐decrease under NSBBs showed better discrimination to predict further‐decompensation than the baseline MELD, Child–Pugh or HVPG, by time‐dependent ROC‐curves (c‐statistic >70%). At each stage, patients without HVPG‐decreases, either ≥10% or ≥20% from the baseline, had higher risk of further‐decompensation (sHR from 2.43 to 6.73, p < .01) and worse survival.

Conclusions

In each stage of decompensated cirrhosis, mortality risk significantly and very markedly increase with further‐decompensation. HVPG‐non‐response to NSBBs may adequately stratify the risk of further decompensation and death, in each stage. This suggests potential benefit with pre‐emptive therapies in HVPG‐non‐responders at each‐stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalLiver CirrhosisAscitesGastrointestinal HemorrhageEsophageal and Gastric VaricesPortal PressureHumansFemaleMaleMiddle AgedAgedPrognosisAdrenergic beta-AntagonistsROC Curve

Stichwörter der Autor:innen

HVPG‐changesclinical stagesdecompensated‐cirrhosisfurther‐decompensation

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
  • Biostatistics Unit, Medical School, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Medical Statistics Core Faculty, IDIBAPS, Hospital Clinic, Barcelona, Spain.

ORCID-Profile: Marta Garcia-Guix, Alba Ardevol, Edilmar Alvarado-Tápias, Àngels Escorsell, Càndid Villanueva

Zitieren

APA

Garcia-Guix, M., Ardevol, A., Sapena, V., Alvarado-Tápias, E., Huertas, A., Brujats, A., Fajardo, J., Cuyas, B., Poca, M., Guarner, C., Torras, X., Escorsell, À., & Villanueva, C. (2024). Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes. Liver International. https://doi.org/10.1111/liv.15937

Vancouver

Garcia-Guix M, Ardevol A, Sapena V, Alvarado-Tápias E, Huertas A, Brujats A, et al. Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes. Liver International. 2024. doi:10.1111/liv.15937

BibTeX
@article{GarciaGuix2024,
  author = {Garcia-Guix, Marta and Ardevol, Alba and Sapena, Victor and Alvarado-Tápias, Edilmar and Huertas, Anna and Brujats, Anna and Fajardo, Javier and Cuyas, Berta and Poca, María and Guarner, Carlos and Torras, Xavier and Escorsell, Àngels and Villanueva, Càndid},
  title = {Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15937}
}
Kostenlos starten →